SCHEMBL2934831

SCHEMBL2934831

Nc1ncc2nc(Br)[nH]c2n1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
CDC7 O00311 2/20 0.35
GRM4 Q14833 1/20 0.34
ALDH1A1 P00352 1/20 0.33
EGFR P00533 1/20 0.33
FGFR1 P11362 1/20 0.32
JAK1 P23458 1/20 0.31
TYK2 P29597 1/20 0.31
CLK1 P49759 2/20 0.31
CDK5 Q00535 1/20 0.31
CDK5R1 Q15078 1/20 0.31
PARP16 Q8N5Y8 1/20 0.31
PARP3 Q9Y6F1 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
HSP90AA1 P07900 1/20 0.30
HSP90AB1 P08238 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29802574 0.79 ALDH1A1 (0.38) ALDH1A1CLK1
SCHEMBL1644969 0.79 ALDH1A1 (0.38) ALDH1A1CLK1
SCHEMBL7068564 0.76 PDK2 (0.42) CDK5CDK5R1
SCHEMBL5942175 0.76 BCL6 (0.35) GRM4ALDH1A1CDK5CDK5R1
SCHEMBL29229228 0.76 TYRO3 (0.43) ALDH1A1EGFR
SCHEMBL1963573 0.73 ADORA2A (0.36) ADORA2AADORA1EGFR
SCHEMBL25449335 0.72 L3MBTL1 (0.42) ALDH1A1
SCHEMBL29283717 0.72 KDM4E (0.42) ALDH1A1
SCHEMBL25377896 0.72 KDM4E (0.38) ALDH1A1
SCHEMBL26287276 0.72 ALDH1A1 (0.31) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118931997-A Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis 上海飞腾医药科技有限公司 2024-11-12 CN disclosed
EP-1925675-B1 Process for production of nucleoside compound MITSUI CHEMICALS INC (JP) 2010-02-03 EP disclosed
EP-1338654-B1 PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND MITSUI CHEMICALS INC (JP) 2008-10-15 EP disclosed
US-7381820-B2 α-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2′-deoxy-2′-fluoro-β-d-arabinonucleoside YAMASA CORPORATION (JP) 2008-06-03 US disclosed
EP-1178051-B1 PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE MITSUI CHEMICALS INC (JP) 2008-05-28 EP disclosed
EP-1925675-A1 Process for production of nucleoside compound Mitsui Chemicals, Inc. (JP) 2008-05-28 EP disclosed
US-20070135627-A1 Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside KOHEL YAMADA, ETAL 2007-06-14 US disclosed
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside MITSUI CHEMICALS, INC. (JP) 2006-07-27 US disclosed
EP-1676853-A1 ALPHA-1-PHOSPHORYLATED-2-DEOXY-2-FLUOROARABINOSIDE AND PROCESS FOR PRODUCING 2 -DEOXY-2 -FLUORO-BETA-D-ARABINONUCLEOSID E YAMASA CORPORATION (JP) 2006-07-05 EP disclosed
US-20060094869-A1 Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside MITSUI CHEMICALS, INC. (JP) 2006-05-04 US disclosed
EP-1179598-A1 PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND Mitsui Chemicals, Inc. (JP) 2002-02-13 EP disclosed
EP-1178051-A2 PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE Mitsui Chemicals, Inc. (JP) 2002-02-06 EP disclosed
EP-1177201-A1 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES YAMASA CORPORATION (JP) 2002-02-06 EP disclosed
EP-1177202-A1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORPORATION (JP) 2002-02-06 EP disclosed
US-6333315-B1 FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-12-25 US disclosed
US-6291670-B1 VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-09-18 US disclosed
WO-2000069876-A1 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES YAMASA CORPORATION (JP) 2000-11-23 WO disclosed
WO-2000069877-A1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORPORATION (JP) 2000-11-23 WO disclosed
US-6103707-A TREATMENT OF HERPES SIMPLEX VIRUS 1 (HSV-1), HERPES SIMPLEX VIRUS 2 (HSV-2), HUMAN CYTOMEGALOVIRUS (HCMV) AND VARICELLA-ZOSTER VIRUS YAMASA CORPORATION (JP) 2000-08-15 US disclosed
EP-0839813-A1 9-(2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSYL)PURINE DERIVATIVES YAMASA CORPORATION (JP) 1998-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094869-A1 Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside PNP, MTAP, GALE ADORA2A 486/4885ADORA1 357/4885CDC7 501/4885
US-20060167241-A1 Method for synthesizing cyclic bisdinucleoside NSUN2, POLR2H, POLB ADORA2A 1364/4885ADORA1 1262/4885CDC7 844/4885
US-20070135627-A1 Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside TYMP, PNP, DUT ADORA2A 314/4885ADORA1 296/4885CDC7 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.